{
  "docId": "019de076-34c7-7046-ba4a-b568cf89a7c9",
  "docSlug": "e7da6c89bd00edfe5ee10f12333167ff",
  "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 43,
  "pageCount": 56,
  "prevPage": 42,
  "nextPage": 44,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 1,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-34c7-7046-ba4a-b568cf89a7c9/43",
  "deckHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9",
  "deckJsonHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9.json",
  "deckAnchorHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9#slide-43",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.88,
        "x": 0.056,
        "y": 0.475
      },
      "kind": "list",
      "text": "BROAD PORTFOLIO TO ERASE CANCER: We believe we have built the deepest pipeline in the industry to comprehensively shut down RAS/MAPK pathway, with the potential to address unmet needs in over 5 million patients globally",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0333ba13-4faa-4a5b-9cb4-ad1a0866bf31",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.88,
        "x": 0.056,
        "y": 0.175
      },
      "kind": "list",
      "text": "EXPERIENCED TEAM WITH TRACK RECORD OF SERIAL SUCCESSES: Seasoned drug developers who have advanced multiple programs from discovery to IND to global approvals",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "338dff23-61ef-450a-852b-988d2741f207",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.88,
        "x": 0.056,
        "y": 0.775
      },
      "kind": "list",
      "text": "MULTIPLE POTENTIAL NEAR-TERM AND LONG-TERM VALUE DRIVERS: Focused clinical development plan with multiple combination and monotherapy readouts in 2023 and beyond and a strong research engine to drive best-in-class compounds into the clinic",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7f53e296-3046-42f5-b121-7d316a72cab6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.88,
        "x": 0.056,
        "y": 0.325
      },
      "kind": "list",
      "text": "WORLD-CLASS SCIENTIFIC ADVISORY BOARD: Leading pioneers in KRAS (Shokat, UCSF), SHP2 (Blacklow, HMS), ERK (Corcoran, MGH), RAS/MAPK pathway (Rodriguez-Viciana, UCL; Cichowski, HMS), precision oncology (Demetri, DFCI), and biopharma (Varney, Genentech)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e48f2ce2-3cda-44e2-979a-568a1c35e3e1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.88,
        "x": 0.056,
        "y": 0.625
      },
      "kind": "list",
      "text": "FOUR CLINICAL-STAGE COMPOUNDS: Differentiated profiles including naporafenib, a pivotal-ready pan-RAF inhibitor for NRASm melanoma and Q61X tissue agnostic solid tumors, ERAS-007 ERKi, ERAS-601 SHP2i, and ERAS-801, a CNS-penetrant EGFRi for GBM",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fd1b06e7-9d44-415e-916f-80a7fa37caeb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.044,
        "w": 0.382,
        "x": 0.028,
        "y": 0.044
      },
      "kind": "title",
      "text": "Compelling investment thesis",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c99bc230-4106-480d-8e4c-e38fa68d17d8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "8adcc941-09fe-4e73-9eef-1115e407c45d",
      "evidence": "list/bullet: WORLD-CLASS SCIENTIFIC ADVISORY BOARD: Leading pioneers in KRAS (Shokat, UCSF), SHP2 (Blacklow, HMS), ERK (Corcoran, MGH), RAS/MAPK pathway (Rodriguez-Viciana, UCL; Cichowski, HMS), precision oncology (Demet",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 44,
      "from": 43,
      "beatId": "208ecfc2-9d23-4d32-944a-1372c9b19645",
      "arcName": "Rags to Riches",
      "arcSlug": "rags-to-riches",
      "beatName": "Potential impact and investment thesis",
      "beatSlug": "rags-to-riches-the-breakthrough",
      "evidence": "Slides 43-44 present the investment thesis and potential impact",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}